Emil D. Kakkis
2017
In 2017, Emil D. Kakkis earned a total compensation of $6.7M as President and Chief Executive Officer at Ultragenyx Pharmaceutical, a 51% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $393,000 |
|---|---|
| Option Awards | $4,295,234 |
| Salary | $638,115 |
| Stock Awards | $1,319,303 |
| Other | $39,247 |
| Total | $6,684,899 |
Kakkis received $4.3M in option awards, accounting for 64% of the total pay in 2017.
Kakkis also received $393K in non-equity incentive plan, $638.1K in salary, $1.3M in stock awards and $39.2K in other compensation.
Rankings
In 2017, Emil D. Kakkis' compensation ranked 1,256th out of 14,666 executives tracked by ExecPay. In other words, Kakkis earned more than 91.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,256 out of 14,666 | 91st |
Division Manufacturing | 426 out of 5,772 | 93rd |
Major group Chemicals And Allied Products | 112 out of 2,075 | 95th |
Industry group Drugs | 78 out of 1,731 | 96th |
Industry Pharmaceutical Preparations | 62 out of 1,333 | 95th |
Source: SEC filing on April 27, 2018.
Kakkis' colleagues
We found five more compensation records of executives who worked with Emil D. Kakkis at Ultragenyx Pharmaceutical in 2017.
2017
Jayson Dallas
Ultragenyx Pharmaceutical
Chief Commercial Officer and Executive Vice President
2017
Shalini Sharp
Ultragenyx Pharmaceutical
Chief Financial Officer
2017
Thomas Kassberg
Ultragenyx Pharmaceutical
Chief Business Officers and Executive Vice President
2017
John Pinion
Ultragenyx Pharmaceutical
Chief Quality Officer and Executive Vice President of Translational Sciences
2017
Karah Parschauer
Ultragenyx Pharmaceutical